Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191443 | 0.81 | AAK1 (0.30) | AAK1 | |
| SCHEMBL23792510 | 0.80 | GAA (0.39) | GAACACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL12191439 | 0.80 | MAOB (0.30) | — | |
| SCHEMBL25552586 | 0.79 | GAA (0.38) | GAACACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL25474219 | 0.79 | AAK1 (0.32) | AAK1 | |
| SCHEMBL20806106 | 0.78 | GAA (0.40) | GAA | |
| SCHEMBL14492982 | 0.78 | — | — | |
| SCHEMBL12191441 | 0.77 | AAK1 (0.31) | AAK1 | |
| SCHEMBL12191449 | 0.77 | AAK1 (0.31) | AAK1 | |
| SCHEMBL20849759 | 0.74 | AAK1 (0.30) | AAK1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | ACE, SARS1, ACE2 | GAA 891/4885AAK1 4720/4885CACNA2D1 3799/4885 |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | OAT, MAVS, HAVCR2 | GAA 57/4885AAK1 2569/4885CACNA2D1 4774/4885 |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | SSB, HLA-DRB1, TPMT | GAA 613/4885AAK1 4324/4885CACNA2D1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.